Dr. Martens (LON:DOCS) Releases Earnings Results

Dr. Martens (LON:DOCS) announced its earnings results on Thursday. The company reported GBX (1) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Dr. Martens had a return on equity of 6.89% and a net margin of 3.11%. The company had revenue of £290.40 million for the quarter.

Here are the key takeaways from Dr. Martens’ conference call:

• Revenue fell 9.2% year over year to £292.4 million, and adjusted EBIT swung to a £2.2 million loss from a £3.1 million profit. The decline was concentrated in Europe and DTC, with boots sales down 20% amid unusually hot weather and ongoing pressure on core styles.
• Margin and cost discipline cushioned the sales decline: gross margin rose 80 basis points on a comparable basis to 65.4%, while operating costs benefited from prior cost actions. Management said margin should remain resilient, though some first-half benefits may ease in the second half.
• Debt remained broadly flat year over year at £158.9 million, and covenant net debt to EBITDA was 2.2 times versus a 3.0-times limit. Cash generation was seasonally negative by £66.2 million as the company built working capital ahead of peak trading.
• The company reported encouraging early responses to its With Bouncing Soles campaign, upgraded Brand Centres, and new Spring/Summer sandals range. Management cautioned that the campaign and store results are still early, and the new e-commerce platform has required time to bed in.
• Second-half performance is pivotal: management expects boots to remain a headwind for the rest of FY 2027, with core boot styles still under pressure, and said the business is focused on the key trading weeks ahead. Its full-price mix priorities in the U.K. and DACH are weighted to the second half.

Dr. Martens Trading Down 16.8%

Shares of LON:DOCS traded down GBX 10.90 during trading on Thursday, hitting GBX 54.10. 121,855,430 shares of the company’s stock were exchanged, compared to its average volume of 6,573,813. The company has a current ratio of 2.61, a quick ratio of 1.13 and a debt-to-equity ratio of 108.85. The firm has a market cap of £517.88 million, a P/E ratio of 22.54, a PEG ratio of 6.40 and a beta of 0.26. The firm has a 50-day moving average price of GBX 67.13 and a two-hundred day moving average price of GBX 69.53. Dr. Martens has a 1-year low of GBX 52.10 and a 1-year high of GBX 90.

Insider Buying and Selling at Dr. Martens

In other news, insider Ije Nwokori sold 209,160 shares of the firm’s stock in a transaction on Friday, October 16th. The stock was sold at an average price of GBX 69, for a total value of £144,320.40. Over the last 90 days, insiders acquired 927 shares of company stock valued at $59,965. Corporate insiders own 2.97% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Berenberg Bank reissued a “buy” rating and issued a GBX 110 price target on shares of Dr. Martens in a report on Friday, October 9th. Two analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of GBX 105.

Dr. Martens Company Profile

Dr. Martens is an iconic British footwear brand founded in Northamptonshire, England. Its first silhouette, the 1460 boot – named after the date it was produced – rolled off the production line on 1st April 1960. Originally chosen by workers for their air-cushioned comfort and durability, “Docs” or “DM’s” were later adopted by musicians and subcultural pioneers who took them from the street to the global stage. Over six decades later, Dr. Martens operates in more than 60 countries and employs around 3,600 people.